Kangfang Biotech (Cayman) Co., Ltd. announced that its self-developed bispecific antibody Idafoxi (Ivosidenib, PD-1/VEGF) used in the phase III clinical trial AK112-303/HARMONi-2 for the treatment of PD-L1 positive non-small cell lung cancer has been selected as a late-breaking abstract for the 2024 World Lung Cancer Conference and will be orally presented by the principal investigator Professor Zhou Caicun. Idafoxi showed significant efficacy in the phase III clinical trial and performed better than Pembrolizumab. The company has submitted a new indication application to the China National Medical Products Administration. Idafoxi currently has one indication approved in China, and multiple phase III clinical trials are underway, including international multicenter trials and clinical trials for 16 different indications. This news was released by the company's Chairman and Executive Director Dr. Xia Yu on August 12, 2024.

Kangfang Biotech (Cayman) Co., Ltd. announced that its self-developed bispecific antibody Idafoxi (Ivosidenib, PD-1/VEGF) used in the phase III clinical trial AK112-303/HARMONi-2 for the treatment of PD-L1 positive non-small cell lung cancer has been selected as a late-breaking abstract for the 2024 World Lung Cancer Conference and will be orally presented by the principal investigator Professor Zhou Caicun. Idafoxi showed significant efficacy in the phase III clinical trial and performed better than Pembrolizumab. The company has submitted a new indication application to the China National Medical Products Administration. Idafoxi currently has one indication approved in China, and multiple phase III clinical trials are underway, including international multicenter trials and clinical trials for 16 different indications. This news was released by the company's Chairman and Executive Director Dr. Xia Yu on August 12, 2024.